Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma.

Abstract	Four of 12 Chinese patients receiving BACOP, in combination with recombinant human granulocyte colony-stimulating factor, for aggressive non-Hodgkin's lymphoma developed a rapidly progressive pneumonic illness characterised by diffuse pulmonary infiltrates and hypoxaemia. The condition proved fatal in three, and in none could an infective cause be identified. A retrospective analysis revealed only one episode of pneumonia in the previous 24 patients in whom the same BACOP regimen was administered without granulocyte colony-stimulating factor support. Granulocyte colony-stimulating factor, by augmenting white cell production, pulmonary sequestration and margination and production of toxic oxygen species, may exacerbate underlying subclinical bleomycin pulmonary toxicity. Caution should be exercised before using granulocyte-stimulating factors in bleomycin-containing regimens.
Authors	K I Lei, W T Leung, P J Johnson
Journal	British journal of cancer (Br J Cancer) Vol. 70 Issue 5 Pg. 1009-13 (Nov 1994) ISSN: 0007-0920 [Print] England
PMID	7524599 (Publication Type: Comparative Study, Journal Article)
Chemical References	Recombinant Proteins Bleomycin Granulocyte Colony-Stimulating Factor Vincristine Doxorubicin Cyclophosphamide Prednisone
Topics	Adult Aged Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use) Bleomycin (administration & dosage, adverse effects) Cyclophosphamide (administration & dosage, adverse effects) Doxorubicin (administration & dosage, adverse effects) Female Granulocyte Colony-Stimulating Factor (adverse effects, therapeutic use) Humans Lung Diseases (chemically induced) Lymphoma, Non-Hodgkin (drug therapy) Male Middle Aged Prednisone (administration & dosage, adverse effects) Recombinant Proteins (adverse effects, therapeutic use) Retrospective Studies Vincristine (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!